Related Experiment Video
Updated: Sep 26, 2025
08:58
En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
Published on: February 25, 2016
9.7K
Trimethylamine N-oxide in cardiovascular disease
Radosław Andrzej Konieczny1, Wiktor Kuliczkowski2
1Clinical Department of Gastroentrology and Hepatology, Wroclaw Medical University, Poland.
Summary
Trimethylamine N-oxide (TMAO), a gut microbe byproduct, is a significant prognostic marker for cardiovascular disease (CVD). Research explores TMAO metabolism and interventions to reduce its harmful effects in CVD patients.
Area of Science:
- Microbiology
- Cardiology
- Metabolomics
Background:
- Cardiovascular disease (CVD) poses a high mortality and morbidity risk despite established risk factors.
- The gut microbiota is increasingly recognized as a key player in CVD pathogenesis.
- Trimethylamine N-oxide (TMAO) is a microbial metabolite linked to CVD risk.
Purpose of the Study:
- To explore the role of TMAO in cardiovascular disease.
- To understand TMAO metabolism and its pathophysiological implications.
- To review current research on TMAO as a prognostic marker and potential therapeutic target in CVD.
Main Methods:
- Literature review of studies investigating TMAO in various patient populations.
- Analysis of research on TMAO metabolism and its connection to atherosclerotic CVD and heart failure (HF).
- Examination of interventions aimed at reducing TMAO levels and mitigating its adverse effects.
Main Results:
- TMAO levels are influenced by individual factors and gut microbiota composition.
- TMAO has emerged as a significant prognostic marker in cardiovascular disease.
- Studies indicate potential interventions to lower TMAO concentrations and their detrimental impact.
Conclusions:
- TMAO is a crucial link between gut microbiota and cardiovascular health.
- Further research into TMAO metabolism and targeted interventions is warranted for improved CVD management.
- Understanding TMAO pathways offers new avenues for molecular and clinical insights into CVD.
More Related Videos
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
793
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
793
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
239
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
239
01:26Atherosclerosis III: Management
52
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
52
01:28Nitric Oxide Signaling Pathway
5.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
01:23Antihypertensive Drugs: Vasodilators
675
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
675
01:29Preparation of Amines: Reduction of Oximes and Nitro Compounds
4.1K
Oximes can be reduced to primary amines using catalytic hydrogenation, hydride reduction, or sodium metal reduction. The reduction of aliphatic and aromatic nitro compounds to primary amines takes place by either catalytic hydrogenation or by using active metals like Fe, Zn, and Sn in the presence of an acid.
Though catalytic hydrogenation can reduce nitrobenzenes, the reduction is nonselective in the presence of other functional groups. For instance, if nitrobenzene contains an aldehyde group,...
Though catalytic hydrogenation can reduce nitrobenzenes, the reduction is nonselective in the presence of other functional groups. For instance, if nitrobenzene contains an aldehyde group,...
4.1K